Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
NCT02418000 · Spirita Oncology, LLC · PHASE1/PHASE2 · terminated · last registry update 2019-03-20 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Insufficient efficacy in Phase 1 dose-escalation portion of study” | Open Targets' class: negative | Registry record, Spirita Oncology, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAP2K1 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision